Myasthenia gravis and azathioprine treatment: Adverse events related to thiopurine S-methyl-transferase (TPMT) polymorph

Verrouillé
Avatar du membre

Auteur du sujet
Pboulanger Prés.
Administrateur
Administrateur
Messages : 10762
Enregistré le : 02 févr. 2010 18:41
14
Localisation  : La Chapelle en Serval F-60520
Genre :
Zodiaque :
Âge : 67
    Windows 10 Firefox

Myasthenia gravis and azathioprine treatment: Adverse events related to thiopurine S-methyl-transferase (TPMT) polymorph

Message par Pboulanger Prés. »

:hi:Traitement de la myasthénie grave et de l'azathioprine: événements indésirables liés aux polymorphismes de la thiopurine S-méthyl-transférase (TPMT).

:arrow:  Lu sur : https://www.ncbi.nlm.nih.gov/pubmed/32070863

 
[hr]
[/hr]

Traduction disponible directement en cliquant en bas a droite de ce message sur l'expression Traduire en

Image
[hr]
[/hr]
Titre de l'article Myasthenia gravis and azathioprine treatment: Adverse events related to thiopurine S-methyl-transferase (TPMT) polymorphisms.

Date de l'article J Neurol Sci. 2020 Feb 12;412:116734. doi: 10.1016/j.jns.2020.116734. [Epub ahead of print]

Contenu de l'article

Azathioprine (AZA) is the most common immunosuppressive drug used to treat myasthenia gravis (MG).

To analyses the prevalence of thiopurine S-methyl-transferase (TPMT) genotypes and their association with adverse events due to azathioprine therapy in MG patients.

Allele-specific polymerase chain reaction (PCR) and PCR with restriction fragment length polymorphism (RFLP) analysis were carried out to determine the prevalence of the most common TPMT genotypes (*2, *3A, *3B and *3C) in 50 MG patients from Southern Brazilian.

The frequency of adverse reactions due to azathioprine therapy was analysed and correlated with different genotypes groups.

The prevalence of TPMT gene variants was 12%. The allelic frequency of variant TPMT*2 (C238G), TPMT*3A (G460A/A719G), TPMT*3B (G460A), and TPMT*3C (A719G) genotypes was 1, 3, 2 and 1%, respectively.

Adverse events occurred in 44%, of MG patients, of which 86% were minor and 14% were major.

One patient, who presented a major adverse event (bone marrow suppression), was homozygous for the TPMT*3A genotype.

Our study estimated the prevalence of TPMT genotypes for Brazilian MG patients.

The profile of TPMT genotypes was different from other Brazilian populations. Hardy-Weinberg equilibrium and allelic frequencies of TPMT*3A and TPMT*3B, respectively, were different than expected, a finding that suggests a possible founder effect.
Major adverse events were statistically significant for TPMT genotypes compared to wild-type.
Although TPMT genotype has been associated with AZA-related adverse events, since no statistically significant difference among wild-type and other TPMT genotypes for minor adverse events, our study supports the view that TPMT genotype alone is not enough to adequately personalise the AZA therapy in MG patients.

In conclusion, these results were important to characterise the prevalence of TPMT gene variants in MG patients treated with AZA and correlate the adverse events of this therapy in a real-world outpatient clinic from Southern Brazil.
 
[hr]
[/hr]

Message d' un membre de l'équipe technique
Pour les utilisateurs d'I-phone
ci-dessous le lien vers Google Trad

https://translate.google.fr/translate?h ... 2F32070863
Message d' un membre de l'équipe technique
Nous utilisons des services automatiques de traduction fournis
par Yandex ou Google.
Soyez vigilant sur le risque de contre-sens inhérent à ce genre d'outils.
 
[hr]
[/hr]


Sur demande de nos donateurs, nous pouvons faire l'acquisition d'un tiré-à-part de l'article intégral
Le coût de est pris en charge par l'Association

 
[hr]
[/hr]


 
Amicalement,
Image
Verrouillé

Retourner vers « 2020 »